Find Clinical Trial

Home » Find Clinical Trials » A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL

A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL

← Back

Study Phase	Phase 2-3

Therapeutic Area	Cancers

Indication	Blood cancer

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S.)

Active substance/ Medical device	Calaspargase pegol, S095015

Active Substance Code	S095015

Protocol Code	CL2-95015-001

NCT Code	NCT04817761

Documents and links

Results are not yet available.

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.